Kanglong Huacheng Plans $5 Billion Expansion of Production Capacity: What’s the Confidence?

Kanglong Huacheng, a leading domestic CRO company, revealed two major expansion plans with a total investment of $5 billion. The company intends to invest $2 billion to establish a new drug commercial production and CDMO R&D production service base in Qiantang District, Hangzhou, expected to be operational by 2029. Additionally, Kanglong Huacheng plans to set up a wholly-owned subsidiary, Kanglong Huacheng (Hangzhou) New Drug Production Co., Ltd., to oversee the investment, construction, and operation of the commercial production and CDMO R&D production service base in Hangzhou.